1
|
Evaluation of Bax and Bak gene mutations and expression in breast cancer. BIOMED RESEARCH INTERNATIONAL 2014; 2014:249372. [PMID: 24672785 PMCID: PMC3933335 DOI: 10.1155/2014/249372] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 04/28/2013] [Accepted: 11/11/2013] [Indexed: 02/07/2023]
Abstract
Genetic analyses have provided evidence to suggest that Bax and Bak are the essential genes for apoptosis in mammalians cells. This study aimed to search for biomarkers in breast cancer to be used as prognostic markers for the disease. The Bak and Bax genes expressions were analyzed in 23 breast cancer patients by RT-PCR technique. SSCP technique was used to detect the mobility of the abnormal fragment in Bak exon 4. PCR for Bax promoter was digested with Tau 1 restriction enzyme to identify a single polymorphism G(-248)A. The expression of Bak gene is related to several clinical factors of breast cancer. The analysis of Bax RNA showed 4 isoforms of Bax with different distributions in the normal and tumor tissues. These isoforms were Bax α, d, δ, and ζ. Exon 4 had a normal pattern in all cases of breast cancer. There was a statistically significant difference in the frequency distribution of the G(-248)A genotypes in the breast cancer tissues with grade 3+high, T2 stage, lobular +other, and PR −ve subgroups. In this study, Bak expression seems to lead to development of breast cancer and affects the disease progression. Also, Bax d and Bax δ could be used as risk factor and biomarker for breast cancer with the distribution of G284A.
Collapse
|
2
|
Mendoza-Rodriguez M, Arreola H, Valdivia A, Peralta R, Serna H, Villegas V, Romero P, Alvarado-Hernández B, Paniagua L, Marrero-Rodríguez D, Meraz MA, Salcedo M. Cellular retinol binding protein 1 could be a tumor suppressor gene in cervical cancer. INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY 2013; 6:1817-1825. [PMID: 24040446 PMCID: PMC3759488] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Received: 07/06/2013] [Accepted: 07/28/2013] [Indexed: 06/02/2023]
Abstract
AIMS Cervical Cancer (CC) is one of the most important health problems in women. It frequently presents genetic changes at chromosome region 3q21. This region contains the Cellular Retinol Binding Protein 1 gene (CRBP1) which has been implicated as an important element in the development of other types of cancer. The main goal of the present work was to determine the molecular alterations of CRBP1 and its relationship to CC. METHODS To determine the molecular alterations of CRBP1 gene in CC; twenty-six CC and twenty-six healthy cervix samples were evaluated for: 1) Copy number gain by real-time PCR analysis, 2) expression levels by an immunohistochemistry assay on tissue microarray, and 3) the methylation status of the CRBP1 promoter region. RESULTS The increase in CRBP1 copy number was observed in 10 out of the 26 CC samples analyzed, while healthy cervices samples showed no changes in the copy number. In addition, there was a lack of expression of the CRBP1 gene in an important number of the CC samples (17/26), and the CRBP1 gene promoter was methylated in 15/26 of the CC samples. Interestingly, there was a significant association between the lack of expression of the CRBP1 gene and its methylation status. CONCLUSIONS The data indicates that, both activating and inactivating changes in the CRBP1 gene could be significant events in the development and progression of CC, and the lack of expression of the CRBP1 protein could be related with to the development of CC. We believe that there is enough evidence to consider to CRBP1 gene as a tumor suppressor gene for CC.
Collapse
MESH Headings
- Biomarkers, Tumor/genetics
- Biomarkers, Tumor/metabolism
- Carcinoma, Squamous Cell/genetics
- Carcinoma, Squamous Cell/metabolism
- Carcinoma, Squamous Cell/pathology
- Case-Control Studies
- DNA Copy Number Variations
- DNA Methylation
- Female
- Gene Dosage
- Gene Expression Regulation, Neoplastic
- Genes, Tumor Suppressor
- Genetic Predisposition to Disease
- HeLa Cells
- Humans
- Middle Aged
- Phenotype
- Promoter Regions, Genetic
- Retinol-Binding Proteins, Cellular/genetics
- Retinol-Binding Proteins, Cellular/metabolism
- Uterine Cervical Neoplasms/genetics
- Uterine Cervical Neoplasms/metabolism
- Uterine Cervical Neoplasms/pathology
Collapse
Affiliation(s)
- Mónica Mendoza-Rodriguez
- Laboratorio de Oncogenómica, Unidad de Investigación Médica en Enfermedades Oncológicas, UMAE Hospital de OncologíaCMN SXXI, IMSS Av. Cuauhtémoc 330, Col. Doctores, México D.F. 06720
- Departamento de Biomedicina Molecular, Centro de Investigación y de Estudios AvanzadosIPN, México
- Actual address: AV, Centro Interdisciplinario de Ciencias de la Salud, Unidad Milpa Alta, Instituto Politécnico NacionalMéx
| | - Hugo Arreola
- Laboratorio de Oncogenómica, Unidad de Investigación Médica en Enfermedades Oncológicas, UMAE Hospital de OncologíaCMN SXXI, IMSS Av. Cuauhtémoc 330, Col. Doctores, México D.F. 06720
- Actual address: AV, Centro Interdisciplinario de Ciencias de la Salud, Unidad Milpa Alta, Instituto Politécnico NacionalMéx
| | - Alejandra Valdivia
- Laboratorio de Oncogenómica, Unidad de Investigación Médica en Enfermedades Oncológicas, UMAE Hospital de OncologíaCMN SXXI, IMSS Av. Cuauhtémoc 330, Col. Doctores, México D.F. 06720
| | - Raúl Peralta
- Laboratorio de Oncogenómica, Unidad de Investigación Médica en Enfermedades Oncológicas, UMAE Hospital de OncologíaCMN SXXI, IMSS Av. Cuauhtémoc 330, Col. Doctores, México D.F. 06720
| | - Humberto Serna
- Clínica de Colposcopía, Hospital General de MéxicoS.S., México
| | - Vanessa Villegas
- Laboratorio de Oncogenómica, Unidad de Investigación Médica en Enfermedades Oncológicas, UMAE Hospital de OncologíaCMN SXXI, IMSS Av. Cuauhtémoc 330, Col. Doctores, México D.F. 06720
| | - Pablo Romero
- Laboratorio de Oncogenómica, Unidad de Investigación Médica en Enfermedades Oncológicas, UMAE Hospital de OncologíaCMN SXXI, IMSS Av. Cuauhtémoc 330, Col. Doctores, México D.F. 06720
| | | | - Lucero Paniagua
- Laboratorio de Oncogenómica, Unidad de Investigación Médica en Enfermedades Oncológicas, UMAE Hospital de OncologíaCMN SXXI, IMSS Av. Cuauhtémoc 330, Col. Doctores, México D.F. 06720
| | - Daniel Marrero-Rodríguez
- Laboratorio de Oncogenómica, Unidad de Investigación Médica en Enfermedades Oncológicas, UMAE Hospital de OncologíaCMN SXXI, IMSS Av. Cuauhtémoc 330, Col. Doctores, México D.F. 06720
| | - Marco A Meraz
- Departamento de Biomedicina Molecular, Centro de Investigación y de Estudios AvanzadosIPN, México
| | - Mauricio Salcedo
- Laboratorio de Oncogenómica, Unidad de Investigación Médica en Enfermedades Oncológicas, UMAE Hospital de OncologíaCMN SXXI, IMSS Av. Cuauhtémoc 330, Col. Doctores, México D.F. 06720
| |
Collapse
|
3
|
Abstract
Bcl-2 Family Proteins in Development and Treatment of Malignant DiseasesProteins of Bcl-2 family are key regulators of mitochondrial pathway of apoptosis. Deregulation of apoptosis disrupts the complex and delicate balance between cell proliferation, survival and death and plays an important role in the development of malignant diseases. In addition to uncontrolled proliferation, alterations in apoptotic proteins are frequently associated with resistance of malignant cells to chemotherapy, leading to ineffective treatment with chemotherapy that primarily acts by apoptosis initiation. Despite the progress in combinatory and biologic therapy, response rates for treatment of different malignant diseases are not high enough. Therefore, new anti-cancer agents that selectively kill tumour cells and spare normal tissues are still urgently needed. Progress in biochemistry and cell biology leading to detailed dissection of cell signalling pathways allows development of new therapeutic strategies targeting different proteins involved in malignant transformation and uncontrolled proliferation of malignant cells. Emerging knowledge on molecular mechanisms of apoptosis deregulation in cancer development has revealed Bcl-2 family proteins as potential targets for drugs discovery. Structural analysis of these proteins together with studies of apoptosis mechanisms have outlined strategies for generation of new drugs, resulting in numerous novel chemical entities with mechanism-based activity. Many of the most logical targets for promoting apoptosis of malignant cells are technically challenging, involving often disruption of protein interactions or changes in gene expression, as opposed to traditional pharmaceutical approach that predominantly attacks enzymes. Understanding of the core components of the apoptotic machinery at the molecular and structural levels may lead to new era in cancer therapy where the intrinsic and acquired resistance of malignant cells to apoptosis can be pharmacologically reversed, reinstating natural pathways of cell suicide.
Collapse
|
4
|
Isaian A, Bogdanova NV, Houshmand M, Movahadi M, Agamohammadi A, Rezaei N, Atarod L, Sadeghi-Shabestari M, Tonekaboni SH, Chavoshzadeh Z, Hassani SMS, Mirfakhrai R, Cheraghi T, Kalantari N, Ataei M, Dork-Bousset T, Sanati MH. BAK, BAX, and NBK/BIK Proapoptotic Gene Alterations in Iranian Patients with Ataxia Telangiectasia. J Clin Immunol 2009; 30:132-7. [DOI: 10.1007/s10875-009-9340-6] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2009] [Accepted: 09/29/2009] [Indexed: 11/28/2022]
|
5
|
Kataoka TR, Shinoda H, Yanagawa M, Kamiura S, Nishizawa Y, Hongyo T. Heterologous carcinosarcoma of Douglas' pouch with adenocarcinomas of the fallopian tube and the peritoneal cavity. Pathology 2008; 40:641-5. [PMID: 18752138 DOI: 10.1080/00313020802320721] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
6
|
Abstract
Irrespective of the morphological features of end-stage cell death (that may be apoptotic, necrotic, autophagic, or mitotic), mitochondrial membrane permeabilization (MMP) is frequently the decisive event that delimits the frontier between survival and death. Thus mitochondrial membranes constitute the battleground on which opposing signals combat to seal the cell's fate. Local players that determine the propensity to MMP include the pro- and antiapoptotic members of the Bcl-2 family, proteins from the mitochondrialpermeability transition pore complex, as well as a plethora of interacting partners including mitochondrial lipids. Intermediate metabolites, redox processes, sphingolipids, ion gradients, transcription factors, as well as kinases and phosphatases link lethal and vital signals emanating from distinct subcellular compartments to mitochondria. Thus mitochondria integrate a variety of proapoptotic signals. Once MMP has been induced, it causes the release of catabolic hydrolases and activators of such enzymes (including those of caspases) from mitochondria. These catabolic enzymes as well as the cessation of the bioenergetic and redox functions of mitochondria finally lead to cell death, meaning that mitochondria coordinate the late stage of cellular demise. Pathological cell death induced by ischemia/reperfusion, intoxication with xenobiotics, neurodegenerative diseases, or viral infection also relies on MMP as a critical event. The inhibition of MMP constitutes an important strategy for the pharmaceutical prevention of unwarranted cell death. Conversely, induction of MMP in tumor cells constitutes the goal of anticancer chemotherapy.
Collapse
Affiliation(s)
- Guido Kroemer
- Institut Gustave Roussy, Institut National de la Santé et de la Recherche Médicale Unit "Apoptosis, Cancer and Immunity," Université de Paris-Sud XI, Villejuif, France
| | | | | |
Collapse
|
7
|
Xu JX, Hoshida Y, Hongyo T, Sasaki T, Miyazato H, Tomita Y, Aozasa K. Analysis of p53 and Bak gene mutations in lymphoproliferative disorders developing in rheumatoid arthritis. J Cancer Res Clin Oncol 2006; 133:125-33. [PMID: 16988840 DOI: 10.1007/s00432-006-0152-2] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2006] [Accepted: 08/28/2006] [Indexed: 01/10/2023]
Abstract
PURPOSE Individuals affected by rheumatoid arthritis (RA) occasionally develop lymphoproliferative disorders (RA-LPD). To study the molecular changes underscoring the RA-LPD, mutations of p53 and Bak gene were analyzed in RA-LPD with (MTX-LPD) or without methotrexate treatment for RA (non-MTX-LPD). METHODS Histology and immunophenotype were immunohistochemically examined in 32 cases of MTX-LPD and 21 of non-MTX-LPD. Polymerase chain reaction-single strand conformation polymorphism (PCR-SSCP) followed by direct sequencing was employed to detect the mutations of p53 and Bak gene. RESULTS Frequency of p53 mutations in non-MTX-LPD (47.6%) was significantly higher than that in MTX-LPD (15.6%) (P < 0.05). Among the cases with non-Hodgkin's lymphoma (NHL), the largest category of RA-LPD, the frequency of p53 mutations in the non-MTX-NHL (47.6%) was significantly higher than that in the MTX-NHL (14.8%) (P < 0.05). Interval between the onset of RA and LPD development was significantly longer in LPD with p53 gene mutations (median 228 months) than that without mutations (133 months). LPD with p53 gene mutations had more advanced diseases and an unfavorable prognosis than those without mutations. CONCLUSIONS MTX-LPD and non-MTX-LPD show similar findings in clinical characteristics, histology, EBV positive rate, and frequency of Bak gene mutations. Whereas the non-MTX-LPD is distinct from the MTX-LPD in its significantly higher p53 mutation frequency.
Collapse
Affiliation(s)
- Jing-Xian Xu
- Department of Pathology (C3), Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan
| | | | | | | | | | | | | |
Collapse
|
8
|
Thomadaki H, Scorilas A. BCL2 family of apoptosis-related genes: functions and clinical implications in cancer. Crit Rev Clin Lab Sci 2006; 43:1-67. [PMID: 16531274 DOI: 10.1080/10408360500295626] [Citation(s) in RCA: 174] [Impact Index Per Article: 9.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
One of the most effective ways to combat different types of cancer is through early diagnosis and administration of effective treatment, followed by efficient monitoring that will allow physicians to detect relapsing disease and treat it at the earliest possible time. Apoptosis, a normal physiological form of cell death, is critically involved in the regulation of cellular homeostasis. Dysregulation of programmed cell death mechanisms plays an important role in the pathogenesis and progression of cancer as well as in the responses of tumours to therapeutic interventions. Many members of the BCL2 (B-cell CLL/lymphoma 2; Bcl-2) family of apoptosis-related genes have been found to be differentially expressed in various malignancies, and some are useful prognostic cancer biomarkers. We have recently cloned a new member of this family, BCL2L12, which was found to be differentially expressed in many tumours. Most of the BCL2 family genes have been found to play a central regulatory role in apoptosis induction. Results have made it clear that a number of coordinating alterations in the BCL2 family of genes must occur to inhibit apoptosis and provoke carcinogenesis in a wide variety of cancers. However, more research is required to increase our understanding of the extent to which and the mechanisms by which they are involved in cancer development, providing the basis for earlier and more accurate cancer diagnosis, prognosis and therapeutic intervention that targets the apoptosis pathways. In the present review, we describe current knowledge of the function and molecular characteristics of a series of classic but also newly discovered genes of the BCL2 family as well as their implications in cancer development, prognosis and treatment.
Collapse
Affiliation(s)
- Hellinida Thomadaki
- Department of Biochemistry and Molecular Biology, Faculty of Biology, University of Athens, Panepistimiopolis, 15701 Athens, Greece
| | | |
Collapse
|